BMRN vs. WST: BioMarin Pharmaceutical vs. West Pharmaceutical Services Stock Comparison

Company Profile

BioMarin Pharmaceutical (BMRN) and West Pharmaceutical Services (WST) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMRN is classified in Biotechnology while WST is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile West Pharmaceutical Services (WST) reports 21.23%, ranking against industry peers normally.

BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile West Pharmaceutical Services (WST) reports 18.81%, ranking against industry peers normally.

Both BioMarin Pharmaceutical (BMRN) at 26.58% and West Pharmaceutical Services (WST) at 25.37% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both BioMarin Pharmaceutical (BMRN) at 12.87% and West Pharmaceutical Services (WST) at 6.25% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both BioMarin Pharmaceutical (BMRN) at -18.55% and West Pharmaceutical Services (WST) at 1.49% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

West Pharmaceutical Services (WST) at 2.82 keeps current ratio within its industry’s typical mid-range, while BioMarin Pharmaceutical (BMRN) at 2.44 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMRN.

West Pharmaceutical Services (WST) at 0.11 carries an industry-typical debt-to-equity mix, while BioMarin Pharmaceutical (BMRN) at 0.67 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

BioMarin Pharmaceutical (BMRN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a yield of 0.22%, ranking against industry peers normally.

BioMarin Pharmaceutical (BMRN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a payout of 9.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: West Pharmaceutical Services (WST) trades at 44.87 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.

BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while West Pharmaceutical Services (WST) at 8.20 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.

BioMarin Pharmaceutical (BMRN) at 1.73 is valued about in line with its industry on P/B ratio, while West Pharmaceutical Services (WST) at 9.40 carries an above-peer premium to book — WST is pricier on assets.

Valuation Metrics